COMMUNIQUÉS West-GlobeNewswire

Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement
29/04/2024
Dubai Healthcare Authority Granted Insurance Reimbursement for Biomerica’s EZ Detect™ Colon Disease Screening Test EZ Detect ™ is a simple FDA cleared 2-minute at-home test that detects early warning signs of colorectal [...]
PetMed Express, Inc. Names Sandra Campos as new Chief Executive Officer and President
29/04/2024
Sandra Campos, retail E-commerce veteran, becomes CEO and President, effective immediately, after spending the past year serving on the Company’s Board of Directors and remains on the Board Ms. Campos brings a deep [...]
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery
29/04/2024
MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative, interventional [...]
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
29/04/2024
MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the [...]
Bitterroot Bio Announces Dosing of First Participants in a Phase 1, First-in-Human Study of BRB-002 in Healthy Volunteers
29/04/2024
PALO ALTO, Calif. and MELBOURNE, Australia, April 29, 2024 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, today announced that the first human [...]
Immodulon to Participate in the Wells Fargo Virtual Private Biotech Symposium
29/04/2024
UXBRIDGE, United Kingdom, April 29, 2024 (GLOBE NEWSWIRE) -- Immodulon, a late-stage clinical biotechnology company focused on developing a broad spectrum immunomodulator to improve the lives of patients suffering from [...]
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)
29/04/2024
First Ever Breakthrough Designation for a Drug Being Developed for PWS Designation is Based on Data from the Phase 3 Program for DCCR Planned Submission of a New Drug Application (NDA) for DCCR Remains on Track for Mid- [...]
LifeMD Appoints Dr. Calum MacRae to its Board of Directors
29/04/2024
NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment of Calum MacRae, M.D., Ph.D., a clinician, researcher and [...]
Scorpius Holdings Provides 2023 Year-End Business Update; Reports 570% Sequential Increase in Revenue for the Fourth Quarter of 2023
29/04/2024
DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (‘Scorpius” or “the Company”), an integrated contract development and manufacturing organization providing state-of-the-art [...]
BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID
29/04/2024
Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID Bezisterim, an anti-inflammatory and insulin-sensitizer that permeates the [...]
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
29/04/2024
Nes-Ziona, Israel, April 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company, today issued the following [...]
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
29/04/2024
Boca Raton, Florida, April 29, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune [...]
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
29/04/2024
STOUGHTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious [...]
Corcept Completes Enrollment in Phase 4 CATALYST Trial
29/04/2024
MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic [...]
Late Breaking Abstract Presented at the Japanese Urological Association Annual Meeting on Aquablation Therapy Outcomes for Men in Japan with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
29/04/2024
Japanese post market survey supports safety and efficacy of Aquablation therapy SAN JOSE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics [...]
Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
29/04/2024
Management to host conference call on Thursday, May 9, 2024, at 8:30 a.m. ET FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on [...]
SS Innovations Achieves Pediatric Milestone with First Infant Pyeloplasty Using SSi Mantra Surgical Robotic System
29/04/2024
Company’s flagship SSi Mantra surgical device has now been used in more than 1000 procedures FORT LAUDERDALE, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations [...]
NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease
29/04/2024
NKGen advances its neurodegenerative disease program with FDA IND clearance for its Phase 1/2a SNK01 Clinical Trial in patients with Parkinson’s disease. The Company expects to initiate a Phase 1 clinical trial in PD in [...]
ClearPoint Neuro Announces FDA Clearance of Prism Bone Anchor Accessory
29/04/2024
Key Accessory to the ClearPoint Prism® Neuro Laser Therapy Will Enable Operating Room Placement of Laser Fibers SOLANA BEACH, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “ [...]

Pages